Pt-based drugs: the spotlight will be on proteins

Area of Science:

• Medicinal Chemistry
• Molecular Biology
• Pharmacology

Background:

• Platinum-based drugs are vital anticancer agents, primarily acting by forming DNA adducts.
• While DNA platination is established, interactions with other biomolecules, particularly proteins, are increasingly recognized.

Purpose of the Study:

• To review experimental evidence on protein-cisplatin adduct formation.
• To explore the correlation between protein adducts and the pharmacological profile of platinum drugs.
• To propose an updated model for platinum-based drug mechanisms of action.

Main Methods:

• Literature review of experimental evidence on protein-cisplatin adducts.
• Analysis of the role of Pt-coordinating groups on metal complex reactivity.
• Synthesis of findings to develop a comprehensive mechanistic model.

Main Results:

• Platinum complexes bind to proteins at reactive sites like His, Met, and Cys residues.
• Protein adducts and DNA-protein cross-links are significant factors in cisplatin's mechanism.
• Proteins may act as reaction intermediates or reservoirs for platinum drugs, influencing drug bioavailability and toxicity.

Conclusions:

• The mechanism of platinum-based drugs is more complex than DNA adduct formation alone.
• Proteins are implicated as reactive intermediates in DNA platination.
• Understanding protein interactions is crucial for fully defining the clinical potential of platinum anticancer drugs.